Immunologic characteristics and management and prospects of targeted biological therapy in adults with severe asthma
10.12092/j.issn.1009-2501.2024.04.008
- Author:
Ao SUN
1
;
Jingluan WANG
1
;
Dunqiang REN
1
;
Xiaojing LIU
1
;
Wenjuan LIU
2
Author Information
1. Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University
2. Community Health Service Center
- Publication Type:Journal Article
- Keywords:
asthma phenotypes;
biologics;
severe asthma
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(4):415-422
- CountryChina
- Language:Chinese
-
Abstract:
Severe asthma stands as a formidable contributor to both mortality and morbidity of patients suffering asthma, casting substantial social and economic shadows on communities. As our understanding of asthma's pathophysiology deepens, a beacon of hope emerges in the form of biological targeted therapies, offering a promising avenue for the management of this challenging condition. These therapies, by precisely inhibiting or modulating pivotal molecules in the inflammatory cascade, offer potential benefits in symptom alleviation, lung function enhancement, and risk reduction of acute exacerbations. They signify a paradigm shift in severe asthma treatment. Within the confines of this article, we embark on a systematic exploration of the immunological underpinnings that define severe asthma. By delving into the intricacies of the immune system's role in exacerbating this condition, we aim to offer a comprehensive assessment of both the current landscape and the future prospects of biological therapies. Our objective is to provide a scientifically robust and valuable reference that can guide the individualized treatment of patients grappling with severe asthma.
